Hospital
University of California Irvine
University of California Irvine was paid $6.02M by Medicaid between Jan 2018 and Dec 2024, across 143 billing codes. Its largest line is 0450, Emergency room services — 22% of everything it billed.
33Billing provider infoUNIVERSITY OF CALIFORNIA IRVINE
LOS ALAMITOS, CA 90720
LOS ALAMITOS, CA 90720
33aNPI1568493922assigned 07/05/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.02M
24GClaims329,563
24DCodes billed143
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#213 of 410
Median peer was paid$6.90M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 55,669 | $1.21M | |
| 2019 | 47,462 | $955K | |
| 2020 | 43,131 | $616K | |
| 2021 | 44,792 | $658K | |
| 2022 | 53,657 | $778K | |
| 2023 | 53,493 | $982K | |
| 2024incomplete | 31,359 | $827K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 22% | 34,525 | 30,370 | $1.32M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.9% | 2,382 | 2,073 | $358K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.1% | 4,243 | 3,862 | $310K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.8% | 7,527 | 6,199 | $286K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 4.0% | 14,742 | 12,660 | $239K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 3.4% | 6,003 | 5,275 | $202K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.2% | 1,190 | 1,006 | $193K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.7% | 5,955 | 4,790 | $161K |
| 80053 | Comprehensive metabolic panel | 2.6% | 14,957 | 12,904 | $157K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.6% | 1,573 | 1,447 | $155K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.3% | 23,617 | 19,441 | $139K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 1.9% | 1,994 | 1,832 | $116K |
131 more codes
| A0429 | Emergency ambulance ride, basic life support | 1.9% | 2,967 | $114K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 2,187 | $109K |
| 99199 | Unlisted special service, procedure or report | 1.7% | 1,979 | $103K |
| 99284 | Emergency room visit (serious) | 1.7% | 1,563 | $100K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.6% | 2,252 | $97K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 5,155 | $95K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.5% | 5,106 | $91K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.5% | 1,863 | $91K |
| 84484 | 1.5% | 10,788 | $90K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.3% | 9,651 | $80K |
| J3490 | Unclassified drugs | 1.2% | 10,238 | $73K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 8,147 | $70K |
| 99283 | Emergency room visit (moderate) | 1.1% | 2,020 | $66K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 4,170 | $65K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,754 | $56K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,409 | $54K |
| 0250 | <1% | 1,792 | $50K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 875 | $45K |
| 83880 | <1% | 2,479 | $43K | |
| 83690 | <1% | 7,732 | $42K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 422 | $41K |
| 93971 | <1% | 542 | $39K | |
| 0270 | <1% | 11,445 | $38K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 816 | $37K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,608 | $35K |
| 81001 | <1% | 11,497 | $33K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,909 | $31K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,935 | $27K |
| 93970 | <1% | 292 | $27K | |
| 87040 | <1% | 2,229 | $26K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,926 | $25K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,468 | $21K |
| 0272 | <1% | 4,319 | $21K | |
| 81025 | <1% | 4,424 | $20K | |
| 83605 | <1% | 2,440 | $17K | |
| 76830 | Ultrasound, transvaginal | <1% | 351 | $16K |
| 87631 | <1% | 360 | $16K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,241 | $16K |
| 84703 | <1% | 3,618 | $15K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,799 | $15K |
| 80076 | <1% | 2,313 | $14K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,402 | $14K |
| 0360 | <1% | 739 | $13K | |
| 94664 | <1% | 1,159 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,005 | $11K |
| 87400 | <1% | 1,077 | $11K | |
| 96376 | <1% | 866 | $10K | |
| 83735 | <1% | 2,513 | $10K | |
| 87077 | <1% | 1,744 | $10K | |
| A9270 | Non-covered item or service | <1% | 1,758 | $10K |
| 76770 | <1% | 118 | $8K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 123 | $8K |
| 87186 | <1% | 1,021 | $8K | |
| 90715 | <1% | 273 | $8K | |
| 85610 | <1% | 3,036 | $8K | |
| Z9725 | <1% | 253 | $8K | |
| 73564 | <1% | 389 | $7K | |
| 73630 | <1% | 399 | $7K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 1,959 | $7K |
| 87430 | <1% | 991 | $7K | |
| 82962 | <1% | 3,366 | $7K | |
| 85730 | <1% | 2,000 | $7K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 137 | $6K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 46 | $6K |
| 73610 | <1% | 269 | $6K | |
| 85379 | <1% | 692 | $6K | |
| 72100 | <1% | 287 | $6K | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 1,776 | $5K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 231 | $5K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,206 | $5K |
| 73030 | <1% | 321 | $5K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 444 | $5K |
| J2704 | Injection, propofol, 10 mg | <1% | 742 | $4K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 230 | $4K |
| 73130 | <1% | 248 | $4K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,017 | $3K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 721 | $3K |
| 94760 | <1% | 528 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 233 | $3K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 94 | $3K |
| 0001A | <1% | 69 | $3K | |
| 87081 | <1% | 643 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 603 | $3K |
| Z7502 | <1% | 68 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 450 | $2K |
| 84100 | <1% | 627 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 838 | $2K |
| 85027 | <1% | 486 | $2K | |
| 84702 | <1% | 294 | $2K | |
| 0710 | <1% | 674 | $2K | |
| 86901 | <1% | 855 | $2K | |
| 86900 | <1% | 803 | $2K | |
| 71020 | <1% | 55 | $2K | |
| 76801 | <1% | 44 | $1K | |
| 0011A | <1% | 32 | $1K | |
| A4217 | Sterile water/saline, 500 ml | <1% | 245 | $1K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 188 | $1K |
| 0160 | <1% | 226 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 274 | $1K |
| 87070 | <1% | 34 | $968.84 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 86 | $911.59 |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 32 | $823.98 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 409 | $799.32 |
| 71010 | <1% | 40 | $758.46 | |
| 80306 | <1% | 61 | $701.13 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,146 | $663.05 |
| 0012A | <1% | 15 | $600.00 | |
| 0320 | <1% | 124 | $498.75 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 44 | $348.82 |
| 86850 | <1% | 115 | $320.76 | |
| 82550 | <1% | 49 | $263.80 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 35 | $234.36 |
| 73110 | <1% | 15 | $209.69 | |
| 0761 | <1% | 33 | $192.84 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 56 | $163.02 |
| 84439 | <1% | 19 | $117.39 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12 | $110.10 |
| 87420 | <1% | 51 | $105.06 | |
| 29125 | <1% | 13 | $98.92 | |
| 99070 | <1% | 40 | $81.80 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 14 | $76.24 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 13 | $74.90 |
| A9150 | Non-prescription drugs | <1% | 432 | $2.32 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 13 | $2.31 |
| 0255 | 0% | 13 | $0.00 | |
| 0350 | 0% | 59 | $0.00 | |
| 0370 | 0% | 15 | $0.00 | |
| 0258 | 0% | 14 | $0.00 | |
| 0636 | 0% | 80 | $0.00 | |
| 0300 | 0% | 779 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSIWABESSY, RANDOLPH (VICE PRESIDENT AND CHIEF FINANCIAL)
Parent organizationUNIVERSITY OF CALIFORNIA IRVI
| Provider | Location | Paid |
|---|---|---|
| University of California Irvine | Orange, CA | $153.06M |
| University of California Irvine | Lakewood, CA | $21.51M |
| University of California Irvine | Fountain Valley, CA | $16.83M |
| University of California Irvine | Placentia, CA | $6.87M |
| Uc Regents | Fountain Valley, CA | $39K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.